Related Experiment Video

Updated: May 29, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.7K

Carbohydrate kinase inhibition: a promising strategy in cancer treatment

Archit Jain1, Rudradip Das1, Muskan Giri1

  • 1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat 382355, India.

Drug Discovery Today
|February 6, 2025
PubMed

Insights

Carbohydrate kinases (CKs) are crucial enzymes in metabolism. This review examines their role in cancer and discusses inhibitors for improved cancer therapy.

Area of Science:

  • Biochemistry
  • Enzymology
  • Oncology

Background:

  • Carbohydrate kinases (CKs) are enzymes essential for cellular metabolism, energy production, and biosynthesis.
  • Their activity, involving carbohydrate phosphorylation, is critical for various biological processes.
  • Dysregulation of CKs is implicated in tumor growth and cancer progression.

Purpose of the Study:

  • To review the critical role of carbohydrate kinases in cancer development.
  • To explore the current landscape of CK inhibitors in cancer therapy.
  • To provide insights for the development of novel and improved CK inhibitors.

Main Methods:

  • Literature review of scientific databases.
  • Analysis of studies on carbohydrate kinase function in cancer.
  • Examination of existing and potential therapeutic inhibitors.

Main Results:

  • Carbohydrate kinases are vital for cancer cell metabolism and survival.
  • Inhibitors targeting CKs, including hexokinases, ribokinases, and phosphatidylinositol kinases, are significant in cancer treatment.
  • Current inhibitors show promise, but challenges remain in optimizing efficacy and specificity.

Conclusions:

  • Carbohydrate kinases represent a promising therapeutic target in oncology.
  • Further research into CK inhibitors is essential for advancing cancer treatment strategies.
  • Developing next-generation inhibitors could enhance therapeutic outcomes for cancer patients.
Keywords:
cancercarbohydrate kinasehexokinasephosphatidylinositol kinaseribokinase

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K